BridgeBio Pharma (BBIO) AI Stock Analysis

• Market Cap: $6.14B
• Dividend Yield: N/A
• Average Volume (3M): 2.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: 2285.27%
• EPS Growth: 27.90%
• Country: US
• Employees: 725
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -2.85
• Shares Outstanding: 190,188,630
• 10 Day Avg. Volume: 3,199,228
• 30 Day Avg. Volume: 2,979,617
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 29.80
• Price to Cash Flow (P/CF): -8.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $55.07
• Price Target Upside: 62.40% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17

BridgeBio Pharma's stock score is primarily impacted by its ongoing financial challenges, including negative equity and profitability issues. Despite these hurdles, positive corporate events and technical indicators provide some optimism. However, until sustainable profitability is achieved, the overall risk remains high.

Positive Factors

Product Adoption

Survey results suggest very strong Attruby uptake in both newly diagnosed and Vyndaqel/Vyndamax progressor populations.

Product Efficacy

A greater portion of physicians noted at least a slight edge to Attruby on efficacy versus Vyndaqel/Vyndamax.

Negative Factors

Analyst Expectations

The current consensus for Attruby's 2025 sales is considered low, and expectations are for this number to increase.

BridgeBio Pharma Business Overview & Revenue Model

Company Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

How the Company Makes Money

BridgeBio Pharma makes money primarily through the development and commercialization of pharmaceutical products, targeting genetic diseases. The company generates revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and subsequently selling these drugs in various markets. Additionally, BridgeBio may enter into strategic partnerships and collaborations with other pharmaceutical companies, which can provide milestone payments, licensing fees, and royalties. These partnerships are often crucial in providing funding and resources necessary for the company's research and development activities. Revenue may also be supplemented by grants and subsidies related to genetic research and drug development.

BridgeBio Pharma Financial Statement Overview

Summary

BridgeBio Pharma has shown strong revenue growth but faces significant challenges in profitability and cash flow management. The negative equity and high leverage raise solvency concerns, while reliance on financing indicates a need for sustainable operational improvements.

Income Statement

BridgeBio Pharma has shown significant revenue growth from $9.3M in 2023 to $221.9M in 2024, a strong positive indicator. However, the company has persistent negative net income, resulting in a net profit margin of -241.4% for 2024. The EBIT and EBITDA margins are also severely negative, indicating ongoing operational challenges and high expenses relative to revenue.

Balance Sheet

The company's balance sheet reveals a negative stockholders' equity, which is a significant concern, indicating that liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, highlighting high leverage. These factors suggest financial instability and potential risks in terms of solvency.

Cash Flow

Operating cash flow remains negative at -$520.7M, and free cash flow is also negative, indicating cash outflows exceed inflows from operations and capital expenditure. The free cash flow to net income ratio is slightly improving but remains negative. Cash inflow from financing activities suggests reliance on external financing to manage operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
221.90M	9.30M	77.65M	69.72M	8.25M
	Gross Profit
218.02M	6.86M	74.21M	66.60M	5.16M
	EBIT
-592.97M	-607.37M	-471.87M	-579.75M	-474.48M
	EBITDA
-436.83M	-565.47M	-397.44M	-533.83M	-465.75M
	Net Income Common Stockholders
-535.76M	-643.20M	-493.96M	-639.30M	-483.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
681.10M	434.88M	428.27M	787.51M	607.09M
	Total Assets
919.34M	546.38M	623.04M	1.01B	703.59M
	Total Debt
9.20M	1.74B	1.72B	1.73B	495.79M
	Net Debt
-671.90M	1.36B	1.35B	1.33B	139.71M
	Total Liabilities
2.38B	1.89B	1.87B	1.88B	595.70M
	Stockholders Equity
-1.46B	-1.35B	-1.25B	-870.41M	57.91M
Cash Flow		Free Cash Flow
-521.66M	-529.03M	-425.81M	-546.18M	-407.23M
	Operating Cash Flow
-520.73M	-527.72M	-419.49M	-497.93M	-399.71M
	Investing Cash Flow
60.78M	54.03M	453.15M	-200.83M	-52.99M
	Financing Cash Flow
748.46M	451.54M	-13.13M	736.45M	447.19M

BridgeBio Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 33.91 is above the 20-day moving average (MA) of 33.84, above the 50-day MA of 33.60, and above the 200-day MA of 28.62, indicating a bullish trend. The MACD of 0.40 indicates Positive momentum. The RSI at 45.09 is Neutral, neither overbought nor oversold. The STOCH value of 34.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.

BridgeBio Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRPT	66 Neutral	$5.40B	21.11	19.71%	―	52.97%	―
TGTX	58 Neutral	$5.65B	262.97	12.21%	―	40.80%	100.62%
LEGN	57 Neutral	$5.74B	―	-15.45%	―	119.97%	67.21%
BPMC	52 Neutral	$5.13B	―	-31.26%	―	104.04%	87.80%
RVMD	50 Neutral	$6.26B	―	-29.33%	―	-100.00%	5.49%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
BBIO	46 Neutral	$6.14B	―	35.68%	―	2285.27%	27.90%

BridgeBio Pharma Corporate Events

BridgeBio Pharma Appoints New President and CFO

On March 17, 2025, BridgeBio Pharma announced the departure of its Chief Financial Officer, Brian C. Stephenson, who will transition to a consulting role until March 2026. Thomas Trimarchi, Ph.D., has been appointed as the new President and CFO, a move that positions the company to continue its focus on genetic diseases and potentially enhance its operational strategies.

BridgeBio Pharma Strengthens Financial Position with Note Issuance

On February 28, 2025, BridgeBio Pharma issued $575 million in 1.75% Convertible Senior Notes due 2031 in a private offering to qualified institutional buyers. The proceeds, approximately $563 million after expenses, were used to repay outstanding borrowings under a financing agreement and to repurchase shares of its common stock, with the remaining funds allocated for general corporate purposes. This strategic financial move aims to strengthen BridgeBio’s balance sheet, reduce interest expenses, and provide greater operational flexibility, potentially impacting the company’s market position and stock price.

BridgeBio Pharma Reports Strong Drug Uptake and Trial Progress

BridgeBio Pharma announced significant commercial progress with its FDA-approved drug Attruby, receiving 430 prescriptions from 248 physicians, signaling strong market uptake. Additionally, the company has fully enrolled three major Phase 3 clinical trials and is well-funded, with $406 million in cash and anticipated regulatory milestone payments, positioning it to advance its late-stage pipeline programs and achieve several 2025 milestones.